Silo Pharma $4M Private Placement
Analysis based on 6 articles · First reported Jul 10, 2026 · Last updated Jul 10, 2026
The private placement provides Silo Pharma with immediate capital of $4 million, with potential additional $7.7 million from warrant exercises, strengthening its balance sheet for working capital. The offering may dilute existing shareholders but signals investor confidence in the company's pipeline.
Silo Pharma, Inc. (Nasdaq: SILO) announced a private placement of 619,965 shares of common stock (or pre-funded warrants in lieu thereof), Series A-3 warrants, and short-term Series A-4 warrants at a purchase price of $6.452 per share, raising approximately $4 million in gross proceeds. The warrants have an exercise price of $6.21 per share and are exercisable immediately. The Series A-3 warrants expire five years after the effective date of the Resale Registration Statement, and the Series A-4 warrants expire eighteen months after that date. H.C. Wainwright & Co. acted as exclusive placement agent. The offering is expected to close on July 10, 2026, with net proceeds used for working capital and general corporate purposes. The securities are unregistered and will be offered under Section 4(a)(2) of the Securities Act and Regulation D. Silo Pharma intends to file a resale registration statement with the SEC.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard